JPWO2020037152A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020037152A5 JPWO2020037152A5 JP2021507740A JP2021507740A JPWO2020037152A5 JP WO2020037152 A5 JPWO2020037152 A5 JP WO2020037152A5 JP 2021507740 A JP2021507740 A JP 2021507740A JP 2021507740 A JP2021507740 A JP 2021507740A JP WO2020037152 A5 JPWO2020037152 A5 JP WO2020037152A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- riluzole
- vas
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 12
- 229960004181 riluzole Drugs 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 7
- 229940002612 prodrugs Drugs 0.000 claims description 7
- 206010057666 Anxiety disease Diseases 0.000 claims description 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 241000251468 Actinopterygii Species 0.000 claims description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000000902 placebo Substances 0.000 claims description 2
- 229940068196 placebo Drugs 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023179961A JP2024010017A (ja) | 2018-08-16 | 2023-10-19 | 疾患処置のためのリルゾール口腔内崩壊錠の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862764864P | 2018-08-16 | 2018-08-16 | |
| US62/764,864 | 2018-08-16 | ||
| PCT/US2019/046709 WO2020037152A1 (en) | 2018-08-16 | 2019-08-15 | Use of riluzole oral disintigrating tablets for treating diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179961A Division JP2024010017A (ja) | 2018-08-16 | 2023-10-19 | 疾患処置のためのリルゾール口腔内崩壊錠の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534160A JP2021534160A (ja) | 2021-12-09 |
| JPWO2020037152A5 true JPWO2020037152A5 (es) | 2022-03-02 |
Family
ID=69525906
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507740A Pending JP2021534160A (ja) | 2018-08-16 | 2019-08-15 | 疾患処置のためのリルゾール口腔内崩壊錠の使用 |
| JP2023179961A Pending JP2024010017A (ja) | 2018-08-16 | 2023-10-19 | 疾患処置のためのリルゾール口腔内崩壊錠の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179961A Pending JP2024010017A (ja) | 2018-08-16 | 2023-10-19 | 疾患処置のためのリルゾール口腔内崩壊錠の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210315865A1 (es) |
| EP (1) | EP3836922A4 (es) |
| JP (2) | JP2021534160A (es) |
| KR (1) | KR20210045423A (es) |
| CN (1) | CN112584831A (es) |
| AU (1) | AU2019322889A1 (es) |
| BR (1) | BR112021002692A2 (es) |
| CA (1) | CA3109769A1 (es) |
| EA (1) | EA202190544A1 (es) |
| IL (1) | IL280657A (es) |
| MX (1) | MX2021001563A (es) |
| PH (1) | PH12021550218A1 (es) |
| SG (1) | SG11202100880VA (es) |
| WO (1) | WO2020037152A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4171554A1 (en) * | 2020-06-24 | 2023-05-03 | Biohaven Therapeutics Ltd. | Compositions and methods for treating obsessive-compulsive disorder |
| CA3193824A1 (en) * | 2020-10-05 | 2022-04-14 | Ana PEREIRA | Riluzole for the treatment of alzheimer's disease |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN114177153B (zh) * | 2021-12-20 | 2023-04-07 | 平顶山市第二人民医院 | 一种利鲁唑口崩片及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| AU2003280324A1 (en) * | 2002-11-26 | 2004-06-18 | Alk-Abello A/S | Pharmaceutical allergen product |
| US9241902B2 (en) * | 2003-12-17 | 2016-01-26 | R.P. Scherer Technologies, Llc | Chewable soft capsules containing ungelatinized starch |
| EP2982372B1 (en) * | 2005-04-05 | 2020-08-05 | Yale University | Glutamate modulating agents in the treatment of mental disorders |
| US20080260823A1 (en) * | 2007-04-20 | 2008-10-23 | Sciele Pharma, Inc. | Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea |
| AU2010282948C1 (en) * | 2009-08-10 | 2017-03-02 | Active Biotech, Ab | Treatment of BDNF-related disorders using laquinimod |
| US9041556B2 (en) | 2011-10-20 | 2015-05-26 | Apple Inc. | Method for locating a vehicle |
| US9434704B2 (en) * | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| CN107735077A (zh) * | 2014-11-21 | 2018-02-23 | 拜尔哈文制药股份有限公司 | 利鲁唑的舌下给药 |
| EA038518B1 (ru) * | 2014-11-21 | 2021-09-09 | Биохэйвен Фармасьютикал Холдинг Компани Лтд. | Сублингвальный препарат рилузола |
| JP6827924B2 (ja) * | 2014-11-26 | 2021-02-10 | メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． | イブジラスト及びリルゾールの組み合わせを含む医薬および組成物 |
| MX2017011196A (es) * | 2015-03-03 | 2018-05-22 | Biohaven Pharm Holding Co Ltd | Farmacos precursores de riluzol y sus usos. |
| BR112019015286A2 (pt) * | 2017-01-31 | 2020-03-03 | L. Manfredi Paolo | Compostos para tratamento ou prevenção de transtornos do sistema nervoso e seus sintomas e manifestações e para citoproteção contra doenças e envelhecimento das células e seus sintomas e manifestações |
-
2019
- 2019-08-15 AU AU2019322889A patent/AU2019322889A1/en active Pending
- 2019-08-15 SG SG11202100880VA patent/SG11202100880VA/en unknown
- 2019-08-15 US US17/268,072 patent/US20210315865A1/en active Pending
- 2019-08-15 CA CA3109769A patent/CA3109769A1/en active Pending
- 2019-08-15 JP JP2021507740A patent/JP2021534160A/ja active Pending
- 2019-08-15 EP EP19849456.9A patent/EP3836922A4/en active Pending
- 2019-08-15 WO PCT/US2019/046709 patent/WO2020037152A1/en active Application Filing
- 2019-08-15 EA EA202190544A patent/EA202190544A1/ru unknown
- 2019-08-15 KR KR1020217007246A patent/KR20210045423A/ko active Search and Examination
- 2019-08-15 CN CN201980054201.0A patent/CN112584831A/zh active Pending
- 2019-08-15 MX MX2021001563A patent/MX2021001563A/es unknown
- 2019-08-15 BR BR112021002692-4A patent/BR112021002692A2/pt unknown
-
2021
- 2021-01-28 PH PH12021550218A patent/PH12021550218A1/en unknown
- 2021-02-04 IL IL280657A patent/IL280657A/en unknown
-
2023
- 2023-10-19 JP JP2023179961A patent/JP2024010017A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6931019B2 (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| JP2023002662A5 (es) | ||
| JP2019503365A5 (es) | ||
| JP2022191257A5 (es) | ||
| JP2019515884A5 (es) | ||
| JP2016534063A5 (es) | ||
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| JP2015517523A5 (es) | ||
| JP2010522714A (ja) | 新規な医薬組成物 | |
| JP2019533660A5 (es) | ||
| JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP2019531286A5 (es) | ||
| JPWO2020037152A5 (es) | ||
| JP2022524819A (ja) | カプシド集合調節剤固体製剤 | |
| RU2006126828A (ru) | Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза | |
| JP2015520759A5 (es) | ||
| JPWO2020023324A5 (es) | ||
| JP2009501205A (ja) | 精神病治療用組成物 | |
| JP2014037445A (ja) | 抵抗性統合失調症およびその他のｃｎｓ疾患の治療 | |
| WO2024010030A1 (ja) | 血中マイオスタチン低下剤 | |
| CN115607545B (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 | |
| JPWO2020206289A5 (es) | ||
| US20240150311A1 (en) | Compositions and methods for inhibiting ido1 | |
| JPWO2020234781A5 (es) | ||
| EP2146713B1 (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens |